Mr. Thomas Smeenk reports

HEMOSTEMIX GRANTS STOCK OPTIONS

In accordance with a stock option plan, Hemostemix Inc. granted on July 22, 2026, subject to regulatory approval, a total of 6.28 million options to purchase common shares of Hemostemix to directors, officers, employees and consultants.

Of the 6.28 million options granted, 4,535,000 options vest immediately upon grant, and 1,745,000 options vest as to 50 per cent on July 22, 2026, and 50 per cent on July 22, 2027. After this option issuance, Hemostemix has 20,496,694 options issued and outstanding. Of the options granted, 3.14 million options were issued to directors and officers of Hemostemix. The company relied on Section 5.5(b) of Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions) with the exemption from the formal valuation requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 in respect of the option grant to the directors and officers of Hemostemix, as no securities of the company are listed on a specified market as defined in MI 61-101. Hemostemix relied on Section 5.7(a) of MI 61-101 with the exemption from the minority approval requirements of MI 61-101 and TSX Venture Exchange Policy 5.9 in respect of the option grant to the directors and officers of the company, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the options granted to the directors and officers of the company exceeded 25 per cent of Hemostemix's market capitalization. The compensation committee and board of directors of the company have approved the option grant, and no materially contrary view or abstention was expressed or made by any director in relation to the option grant. The material change report to be filed in relation to the option grant will not be not filed at least 21 days prior to the completion of the option grant as contemplated by MI 61-101. The company believes that this shorter period is reasonable and necessary in the circumstances as the completion of the option grant occurred shortly before the issuance of this news release and the filing of such material change report.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell, an investigational autologous stem cell therapy developed to support circulation in areas affected by diseases of ischemia. VesCell is derived from a patient's own blood and evaluated through structured clinical research. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, and appears clinically relevant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI diabetes-based patient population, the University of British Columbia and the University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.